'First-ever human death of bird flu strain H5N2 confirmed in Mexico: WHO' -Global News
$BNTX
$CVAC
$MRNA
$PFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/15/2026 | $145.00 | Buy | Citigroup | |
| 3/2/2026 | $35.00 | Hold → Buy | Argus | |
| 2/25/2026 | $25.00 | Underperform | RBC Capital Mkts | |
| 2/20/2026 | $25.00 | Underweight | Barclays | |
| 2/12/2026 | $27.00 | Outperform → Neutral | Daiwa Securities | |
| 2/2/2026 | $113.00 | Outperform → Market Perform | Leerink Partners | |
| 1/28/2026 | $25.00 | Equal Weight | Barclays | |
| 1/22/2026 | $135.00 | Overweight → Neutral | Piper Sandler |
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer, an area of high unmet medical needData demonstrated clinically meaningful antitumor activity across all HER2 expression levels and a manageable safety profile, with centrallyi HER2-tested patients showing a confirmed objective response rate of 47.9% in all evaluable patients, 49.3% in patients with prior immune checkpoint inhibitor treatment, and a median progression-free survival of 8.1 monthsLargest trial to date to report results for a HER2-targeted antibody-drug conjugate
Pfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live me
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
6-K - BioNTech SE (0001776985) (Filer)
DEF 14A - Zoetis Inc. (0001555280) (Filer)
DEFA14A - Zoetis Inc. (0001555280) (Filer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Citigroup initiated coverage of Zoetis with a rating of Buy and set a new price target of $145.00
Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00
RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00
Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13D - BioNTech SE (0001776985) (Filed by)
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on May 7, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202